Mangoceuticals, Inc. is taking a significant step in its growth strategy by filing a preliminary offering statement to raise up to $10 million through the sale of its Series D Convertible Cumulative Preferred Stock. This offering, priced at $10 per share, is being conducted on a best-efforts basis and could provide the company with essential capital to enhance its operations and market presence.

Founded in 2021 and based in Dallas, Texas, Mangoceuticals operates in the health and allied services sector, specifically classified under the SIC code 8090. The company is publicly traded on the Nasdaq under the ticker symbol MGRX. Recent filings indicate that the company is actively pursuing various strategies to bolster its financial health and operational capabilities.

The filing details that Mangoceuticals plans to offer up to 1,000,000 shares of its Series D Preferred Stock, with the potential to issue an additional 4,442,661 shares of common stock upon conversion of the preferred shares. This offering aims to generate maximum gross proceeds of $10 million, which the company intends to use to support its business initiatives.

According to the filing, "This Offering Statement also qualifies up to 4,442,661 shares of our Common Stock, par value $0.0001 per share, that may be issued upon conversion or, if applicable, redemption of the Series D Preferred Stock." This indicates a structured approach to financing that may attract investors looking for equity opportunities in a growing company.

The impact of this offering could extend beyond Mangoceuticals itself, potentially influencing other companies within the health services industry. With the company’s recent financial performance, including a net income of $4.7 million and total revenues of $136,621, the capital raised could enhance its competitive positioning.

As for the next steps, the offering will commence within two calendar days after the SEC qualifies the Offering Statement. This process reflects the company's commitment to securing the necessary funding to further its growth ambitions. The preliminary offering statement filed on November 12, 2026, is a crucial part of this strategy, as it lays the groundwork for future financial activities.